LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
- 1st Edition, Volume 18 - January 14, 2022
- Editor: Lucia Morbidelli
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 1 9 0 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 5 5 6 - 5
Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of an… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAnti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients.
In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field.
- Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field
- Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner
- Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field
Cancer researchers, medical scientists, clinicians, graduate students. Pharmacologists
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Cover Image Insert
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Aims and Scope of the Volume
- About the Volume Editor
- Preface
- Contributors
- Chapter 1: Introduction: How tumor-endothelial cell communication within the tumor microenvironment affects angiogenesis
- Abstract
- Introduction
- Tumor microenvironment components
- Biophysical determinants of TME for the control of angiogenesis
- Soluble proangiogenic factors
- Other regulatory systems
- Surface-associated modulators of angiogenesis
- Endogenous negative regulators of angiogenesis
- Heterogeneity of endothelial component as a modifier of antiangiogenic therapy
- Conclusions
- References
- Chapter 2: Antiangiogenic drugs: Chemosensitizers for combination cancer therapy
- Abstract
- Introduction
- Antiangiogenic drugs
- Approved combinatorial regimens with antiangiogenic drugs
- Conclusions
- References
- Chapter 3: Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma
- Abstract
- Introduction
- Colorectal cancer
- Gastric cancer and gastroesophageal junction adenocarcinoma
- Conclusions
- References
- Chapter 4: Antiangiogenic drugs as chemosensitizer in renal cell cancer
- Abstract
- Introduction
- Clinical applications in renal cell cancer
- Conclusions
- References
- Chapter 5: Antiangiogenic drugs as chemosensitizer in genitourinary cancer
- Abstract
- Introduction
- Urothelial cancer
- Testicular germ cell tumor
- Prostate cancer
- Conclusions
- References
- Chapter 6: Antiangiogenic drugs as chemosensitizer in melanoma
- Abstract
- Introduction
- Insights concerning the molecular mechanisms of angiogenesis
- Immune cells in microenvironment and angiogenesis
- Manipulation of angiogenesis by therapeutic agents in melanoma
- Evidence from clinical trials and possible perspectives
- Conclusion
- References
- Chapter 7: Antiangiogenic drugs as chemosensitizers in hematological tumors
- Abstract
- Introduction
- The cross-talk between EPCs and other players in tumor angiogenesis enlights effective drug targets
- The antiangiogenic drugs in hematological malignancies
- Concluding remarks
- References
- Chapter 8: Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data
- Abstract
- Introduction
- Antiangiogenic activity of metronomic chemotherapy in preclinical and clinical setting
- Combinations of metronomic chemotherapy with antiangiogenic drugs
- Conclusions
- References
- Chapter 9: Resistance to antiangiogenic treatments: A review
- Abstract
- Introduction
- Basic concepts in angiogenesis and antiangiogenesis
- Antiangiogenic treatments and classes of resistance mechanisms
- Resistance to antiangiogenic treatments
- Clinical approach to antiangiogenic resistance
- Discussion
- Conclusions
- Future perspectives
- References
- Chapter 10: Predictive “omic” biomarkers of drug response: Colorectal cancer as a model
- Abstract
- Introduction
- Somatic genomics
- Germline pharmacogenetics/genomics
- Transcriptomics
- Epigenomics
- Non-coding RNA
- Proteomics
- Metabolomics
- Discussion and conclusions
- References
- Chapter 11: General conclusions and future perspectives
- Abstract
- General statements on tumor angiogenesis
- Strategies acting on hypoxic, acidic and oxidative environment
- Vascular normalizing strategies
- Control of lymphocyte trafficking into the TME
- Strategies acting on miRNA and epigenetic determinants
- Final considerations
- References
- Index
- No. of pages: 294
- Language: English
- Edition: 1
- Volume: 18
- Published: January 14, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323901901
- eBook ISBN: 9780323905565
LM
Lucia Morbidelli
Dr. Morbidelli’s experience is within the molecular and biochemical pharmacology of angiogenesis and microcirculation and its biological application in diseases and cancer. Through of a plethora of in vitro and in vivo models, she has contributed to the characterization of the pro- and antiangiogenic activities of designed synthetic molecules and natural products and their potential applications in angiogenesis-dependent diseases of the cardiovascular system, ocular disorders, neurovascular diseases and cancer. She co-organized with Professor Bonavida the Fourth International Workshop on “Nitric Oxide in Cancer” held in Sevilla in March 13-14, 2015. The meeting addressed different topics such as NO, mutagenesis, carcinogenesis, tumor promotion and tumor growth; NO regulation of cell death pathways; NO and proliferation and epithelial-mesenchymal transition; Regulation of immune response by NO; Antitumoral activity of NO-based releasing strategies: pre-clinical studies; Antitumoral activity of NO-based releasing strategies: clinical trials.
Affiliations and expertise
Professor, Department of Life Sciences, University of Siena, Siena, ItalyRead Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy on ScienceDirect